LGM Pharma has announced the second phase of its CDMO growth strategy, committing an additional $9 million to its drug product manufacturing facilities in Rosenberg, Texas, and Colorado Springs, Colorado. This new investment follows a previously announced $6 million expansion in Rosenberg in 2025, bringing the company’s total investment across the two sites to $15 million. The funding is intended to increase commercial capacity, expand R&D capabilities, and support continued demand for U.S.-based drug product manufacturing.
At the Rosenberg, Texas facility, LGM Pharma plans to invest $4 million to expand commercial-scale manufacturing suites for suppositories in response to increasing customer and market demand, including growth in women’s health products. The upgrades will also expand R&D capabilities to support formulation and scale-up for suppositories, solutions, suspensions, and semi-solids. The site will remain fully operational throughout construction, with work on the enhancements already underway.
In Colorado Springs, the company will invest $5 million to expand commercial manufacturing capacity for niche, high-value oral solid dose products, including orally disintegrating tablets. The facility serves as LGM Pharma’s center of excellence for oral solid dose development, and the expansion is planned for completion this year to support growing demand for domestic manufacturing. The company noted that the global oral solid dose CDMO market was valued at $43.65 billion in 2024, with North America accounting for approximately 40.5% of global oral solid dose pharmaceutical manufacturing activity.
According to LGM Pharma, these multi-site investments are intended to strengthen pharmaceutical supply chains in the United States. The company positions the expanded finished dose manufacturing capacity at the downstream end of the supply chain as complementary to its global active pharmaceutical ingredient (API) sourcing capabilities upstream. By combining global drug substance sourcing with expanded U.S. finished dose development and manufacturing, LGM Pharma aims to provide integrated support across the full drug product lifecycle.
Earlier in the supply chain, at the drug substance stage, LGM Pharma supports 505(b)(2), NDA, and ANDA programs through a global network of more than 220 pre-qualified API manufacturers. The company’s service portfolio includes tailored API sourcing, contract analytical testing, and CDMO services that span development through commercialization. The new investments are presented as part of a broader effort to give customers greater control and visibility as products move from development to commercial supply.
LGM Pharma reports that upgrades completed in Phase I of the Rosenberg expansion, including implementation of enhanced track-and-trace serialization systems and increased production volumes, now provide a foundation for this second phase of growth. The company states that it is executing the new investments while keeping both the Rosenberg and Colorado Springs facilities fully operational. LGM Pharma says its teams are experienced in managing complex upgrades without sacrificing quality or disrupting customer supply and that it is pursuing an incremental, phased approach to expand capabilities and capacity while maintaining operational continuity.